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Background: The anticoagulant treatment of acute deep venous thrombosis (DVT) has been historically directed toward
the prevention of recurrent venous thromboembolism. However, such treatment imperfectly protects against late
manifestations of the postthrombotic syndrome. By restoring venous patency and preserving valvular function, early
thrombus removal strategies can potentially decrease postthrombotic morbidity.
Objective: A committee of experts in venous disease was charged by the Society for Vascular Surgery and the American
Venous Forum to develop evidence-based practice guidelines for early thrombus removal strategies, including catheter-
directed pharmacologic thrombolysis, pharmacomechanical thrombolysis, and surgical thrombectomy.
Methods: Evidence-based recommendations are based on a systematic review and meta-analysis of the relevant literature,
supplemented when necessary by less rigorous data. Recommendations are made according to the Grading of Recom-
mendations Assessment, Development and Evaluation (GRADE) methodology, incorporating the strength of the
recommendation (strong: 1; weak: 2) and an evaluation of the level of the evidence (A to C).
Results: On the basis of the best evidence currently available, we recommend against routine use of the term “proximal
venous thrombosis” in favor of more precise characterization of thrombi as involving the iliofemoral or femoropopliteal
venous segments (Grade 1A). We further suggest the use of early thrombus removal strategies in ambulatory patients with
good functional capacity and a first episode of iliofemoral DVT of <14 days in duration (Grade 2C) and strongly
recommend their use in patients with limb-threatening ischemia due to iliofemoral venous outflow obstruction (Grade
1A). We suggest pharmacomechanical strategies over catheter-directed pharmacologic thrombolysis alone if resources are
available and that surgical thrombectomy be considered if thrombolytic therapy is contraindicated (Grade 2C).
Conclusions: Most data regarding early thrombus removal strategies are of low quality but do suggest patient-
important benefits with respect to reducing postthrombotic morbidity. We anticipate revision of these guidelines as
additional evidence becomes available. ( J Vasc Surg 2012;55:1449-62.)
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Guideline Description
Grade of
recommendation:
1: Strong
2: Weak
Quality of evidence
A. High
B. Moderate
C. Low or very low
1. Precision in the diagnosis of deep venous thrombosis
1.1. We recommend use of precise anatomic terminology to characterize the most
proximal extent of venous thrombosis as involving the iliofemoral veins, with
or without extension into the inferior vena cava; the femoropopliteal veins; or
isolated to the calf veins in preference to simple characterization of a
thrombus as proximal or distal.
1 A
1.2. If iliofemoral venous thrombosis is suspected but not confirmed using standard
diagnostic modalities such as venous ultrasound imaging, we recommend the
use of adjunctive imaging modalities, such as computed tomography
venography or magnetic resonance venography to characterize the most
proximal thrombus extent.
1 C
2. Indications for early thrombus removal
2.1. We suggest a strategy of early thrombus removal in selected patients meeting the
following criteria (a) a first episode of acute iliofemoral deep venous thrombosis,
(b) symptoms14 days in duration, (c) a low risk of bleeding, and (d)
ambulatory with good functional capacity and an acceptable life expectancy.
2 C
2.2. We recommend early thrombus removal strategies as the treatment of choice in
patients with limb-threatening venous ischemia due to iliofemoral deep
venous thrombosis with or without associated femoropopliteal venous
thrombosis (phlegmasia cerulea dolens).
1 A
2.3. We recommend that patients with isolated femoropopliteal deep venous
thrombosis be managed with conventional anticoagulation therapy because
there is currently insufficient evidence to support early thrombus removal
strategies in this patient population.
1 C
3. Techniques for early thrombus removal
3.1. We suggest percutaneous catheter-based techniques (pharmacologic or
pharmacomechanical) as first-line therapy for early thrombus removal in
patients meeting the criteria in 1.1.
2 C
3.2. We suggest a strategy of pharmacomechanical thrombolysis be considered over
catheter-directed pharmacologic thrombolysis alone if expertise and resources
are available.
2 C
3.3. We suggest open surgical venous thrombectomy in selected patients who are
candidates for anticoagulation but in whom thrombolytic therapy is
contraindicated.
2 C
4. Periprocedural inferior vena cava filters
4.1. We recommend against routine use of inferior vena cava filters (permanent or
temporary) in conjunction with catheter-directed pharmacologic thrombolysis
of the iliofemoral venous segments.
1 C
4.2. We suggest that the relative risks vs benefits of periprocedural retrievable inferior
vena cava filter placement be considered in patients undergoing
pharmacomechanical thrombolysis and those with thrombus extending into
the inferior vena cava or having markedly limited cardiopulmonary reserve.
2 C
5. Adjunctive use of venous stents
5.1. We recommend the use of self-expanding metallic stents for treatment of
chronic iliocaval compressive or obstructive lesions that are uncovered by any
of the thrombus removal strategies.
1 C
5.2. We suggest that stents not be used in the femoral and popliteal veins. 2 C
6. Early thrombus removal strategies as an adjunct to conventional management
6.1. We recommend that patients managed with early thrombus removal be treated
with a standard course of conventional anticoagulation after the procedure.
1 A
6.2. We recommend that all patients be treated with knee-high compression
stockings (30 to 40 mm Hg) for at least 2 years after the procedure.
1 Ca
t
a
aA first episode of deep venous thrombosis (DVT) is
estimated to occur with a weighted mean age-adjusted
incidence of 50.4/100,000 person-years.1 Historically, the
treatment of acute DVT has been directed toward the
prevention of recurrent venous thromboembolism (VTE) hnd has been defined by randomized clinical trials. These
rials have usually focused on the short-term outcomes after
nticoagulant therapy, using recurrent VTE and bleeding
s primary measures of efficacy and safety.2-4 Such trials
ave indeed established anticoagulation to be safe and
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Volume 55, Number 5 Meissner et al 1451effective, with major hemorrhage in 2% of patients5 and
3-month recurrence rates as low as 5.5%.6 However, the
importance of late manifestations of the postthrombotic
syndrome have been increasingly recognized, and it is clear
that conventional anticoagulation alone provides imperfect
protection against the postthrombotic syndrome. Among
355 patients with a first episode of DVT, the cumulative
incidence of any and severe postthrombotic syndrome at 5
years was 28% and 9.3%, respectively.7 Predictors of more
severe postthrombotic syndrome include involvement of
the common femoral or iliac veins, previous ipsilateral
thrombosis, higher body mass index, older age, and female
sex.8 Although the socioeconomic consequences of severe
postthrombotic syndrome are well recognized, even mild
postthrombotic symptoms may adversely affect quality of
life.9,10
Manifestations of the postthrombotic syndrome result
from a combination of valvular incompetence (reflux) and
residual venous obstruction.11,12 Several strategies for early
thrombus removal have been devised, offering the potential
for early restoration of venous patency and preservation of
valve function. Routine use of systemic thrombolysis for
acute DVT was discouraged by high rates of incomplete
thrombolysis and bleeding complications. For example, a
pooled analysis of six randomized trials found systemically
administered streptokinase was 3.7 times more likely than
heparin to produce “greater than minimal” thrombolysis,
although at the expense of a 2.9-fold increase in major
bleeding complications.13 However, more quantitative
analysis of thrombolytic outcomes has demonstrated com-
plete thrombolysis in as few as 8.9% and no thrombus
reduction in as many as 33.8% of patients treated with
systemic tissue plasminogen activator.14 We recommend
against the use of non–catheter-directed, systemically ad-
ministered thrombolytic agents for the treatment of ilio-
femoral thrombosis.
More directed strategies, including venous throm-
bectomy, catheter-directed pharmacologic thromboly-
sis, and pharmacomechanical thrombolysis, may be more
efficient, with fewer bleeding complications, and likely
have a role in the treatment of acute DVT. Surgical
thrombectomy typically uses a catheter-mounted com-
pliant balloon to remove thrombus from the iliac veins
via a groin incision combined with techniques to remove
associated distal thrombus. Adjunctive construction of a
temporary arteriovenous fistula is commonly recom-
mended to reduce early rethrombosis.15
Catheter-directed pharmacologic thrombolysis is an
image-guided technique involving infusion of thrombo-
lytic agents through a multi-side hole infusion catheter or
wire placed directly into a venous thrombus through a
remote puncture site.16 Pharmacomechanical thrombolysis
uses a number of catheter-based mechanical devices to
deliver the thrombolytic agent as well as to produce some
combination of thrombus fragmentation, distribution of
thrombolytic drugs throughout the thrombus, and/or
thrombus aspiration. These include rotational, rheolytic,
and ultrasound-assisted devices.17The safe application of this technology requires careful
election of those patients most likely to benefit from its
se, considering potential long-term disability, anatomic
istribution of thrombus, duration of symptoms, and the
isk of complications. Unfortunately, proving the efficacy of
hese approaches in preventing the late manifestations of
he postthrombotic syndrome is substantially more difficult
han proving the efficacy of anticoagulants in preventing
ecurrent VTE. Such trials require much longer periods of
ollow-up and validated clinical and quality-of-life measures
ather than dichotomous outcomes such as recurrent VTE.
evertheless, recent data suggest that strategies of early
hrombus removal do indeed have a role in the manage-
ent of acute DVT.18,19
The Society for Vascular Surgery (SVS) and American
enous Forum (AVF) formed a committee of experts in
enous disease to develop evidence-based clinical practice
uidelines regarding strategies of early thrombus removal
or acute DVT. The committee commissioned the conduct
f a systematic review and meta-analysis of the relevant
iterature to inform their recommendations. In contrast to
reviously published systematic reviews,20 this review was
onfined to patients with iliofemoral DVT and excluded
ystemic and locoregional thrombolytic infusion (eg, pedal
ein infusion14) while including surgical thrombectomy.
he results of this systematic review,19 published separately
n this issue of the Journal of Vascular Surgery, forms the
asis of these practice guidelines. When necessary, as for
harmacomechanical thrombolysis and inferior vena cava
IVC) filtration, this review was supplemented by less rig-
rous data, including those from pooled analyses and case
eries.
The recommendations for early thrombus removal are
ade according to the Grading of Recommendations As-
essment, Development and Evaluation (GRADE) ap-
roach21-22 (Table). According to this system, there are
wo components to any treatment recommendation: the
rst is a designation of the strength of the recommendation
strong: 1; or weak: 2) based on the degree of confidence
hat the recommendation will provide more benefit than
arm; the second is an evaluation of the level of evidence (A
o C) based on the confidence that the estimate of effect is
orrect. The strength of a recommendation (1 or 2) reflects
he balance of benefits and risks, as well as cost to the health
are system:
● Grade 1 recommendations are those in which the
benefits of an intervention clearly outweigh its risk and
burdens. All well-informed patients would choose
such a treatment, and the physician can securely rec-
ommend it without a detailed knowledge of the un-
derlying data.
● Grade 2 recommendations are weaker and reflect ther-
apies where the benefits and risks are uncertain or are
more closely balanced. For such interventions, patients
may choose different options based on their underly-
ing values.
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May 20121452 Meissner et alIn accordance with the American College of Chest
Physicians (ACCP) guidelines for the antithrombotic treat-
ment of venous thromboembolic disease,24 we have ad-
opted the language of “recommending” the use of strong
Grade 1 guidelines and “suggesting” the use of weaker
Grade 2 guidelines.
Although trial methodology is related to the quality of
the evidence, clinicians are actually most interested in reli-
able estimates of the benefits and harms associated with a
therapy.21 For high-quality evidence, the effects of therapy
(beneficial or ill) are precise, and further research is unlikely
to change our confidence in the estimate of effect. In
contrast, the estimated effect provided by poor-quality
evidence is unclear and likely to change as better quality
evidence becomes available.
● Grade A, or high-quality evidence, usually comes from
well-executed randomized trials yielding consistent re-
sults, and occasionally, observational studies with large
effects.
● Grade B, or moderate-quality evidence, comes from
randomized clinical trials with important limitations,
inconsistent randomized trials, and strong observa-
tional studies.
● Grade C, or low-quality evidence, includes flawed
randomized trials and most observational studies as
well as data from case reports, descriptive studies, and
expert opinion.
In making recommendations, committee members
considered the available evidence, patients’ values and pref-
erences, availability of surgical expertise, and resource allo-
cation. A systematic process25 was followed whereby initial
guidelines were drafted and submitted, together with the
systematic review,19 to each panel member for comment.
Comments were incorporated into the guidelines and re-
submitted to the panel members for further revision or
acceptance. The process was repeated until there was uni-
Table. Grading of Recommendations Assessment, Develo
recommendations
Recommendation Benefit vs risk Quality
1A Clear High: Consistent re
observational stud
1B Clear Moderate: RCTs wi
strong observatio
1C Clear Low: Observational
Very low: Case serie
expert opinion
2A Balanced or unclear High: Consistent re
observational stud
2B Balanced or unclear Moderate: RCTs wi
strong observatio
2C Balanced or unclear Low: Observational
Very low: Case serie
expert opinion
RCT, Randomized controlled trial.
Adapted from Guyatt G et al.23form agreement on the text of the final recommendations. fccasional differences regarding the grade of recommen-
ation were resolved through additional review of the
vailable data, discussion, and formal vote. On adoption of
he final manuscript, there was a maximum of one dissent-
ng opinion regarding the grade of recommendations 2.1
nd 6.2.
UIDELINES
. Precision in the diagnosis of DVT
1.1. We recommend use of precise anatomic termi-
ology to characterize the most proximal extent of
enous thrombosis as involving the iliofemoral veins,
ith or without extension into the inferior vena cava;
he femoropopliteal veins; or isolated to the calf veins in
reference to simple characterization of a thrombus as
roximal or distal (Grade 1A). Based on perceived dif-
erences in outcomes, DVT has historically been considered
o involve the proximal veins or as isolated to the distal or
alf veins. On the basis of the most central extent of
hrombosis, proximal venous thrombosis includes femoro-
opliteal thrombosis and iliofemoral thrombosis. As de-
ned by the Society of Interventional Radiology,26,27 ilio-
emoral DVT involves complete or partial thrombosis of
he iliac vein or the common femoral vein, or both, with or
ithout femoropopliteal DVT. Femoropopliteal DVT in-
olves the femoral or popliteal venous segments, or both,
ithout extension to the common femoral or iliac veins. It
s becoming increasingly clear that the natural history of
emoropopliteal and iliofemoral thrombosis is significantly
ifferent and that simple stratification of treatment accord-
ng to involvement of the “proximal” or “distal” veins is no
onger adequate.
From a pathophysiologic perspective, thrombolytic
tudies have shown that iliofemoral venous thrombosis is
ssociated with a very high incidence of underlying ana-
omic abnormalities in the iliac veins.16 Compared with
t and Evaluation (GRADE) approach to treatment
dence Comment
from RCTs or
ith large effects
Strong recommendation, generalizable
itations and very
udies
Strong recommendation; may change with
further research
es
criptive reports,
Intermediate recommendation; likely to
change with further research
from RCTs or
ith large effects
Intermediate recommendation: May vary
with patient values
itations and very
udies
Weak recommendation: May vary with
patient values
es
criptive reports,
Weak recommendation: Alternative
treatments may be equally validpmen
of evi
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Volume 55, Number 5 Meissner et al 1453associated with less complete recanalization and a higher
incidence of residual venous obstruction. Although the iliac
segments frequently lack valves, persistent proximal venous
obstruction may be potentially associated with the devel-
opment of reflux in more caudal segments that were not
initially thrombosed.28
Not surprisingly, iliofemoral venous thrombosis is as-
sociated with severe hemodynamic derangements that may
be persistent.29 Acutely, iliofemoral thrombosis may com-
promise the primary venous outflow from the limb with
more severe pain and swelling as well as phlegmasia cerulea
dolens.30 It is also associated with long-term outcomes
such as venous claudication and more severe manifestations
of the postthrombotic syndrome. Venous claudication has
been reported in as many as 43.6% of patients a median of 5
years after iliofemoral DVT.29 Perhaps more importantly,
initial involvement of the common femoral or iliac veins is
associated with a greater increase in objective (Villalta)
postthrombotic scores.8 Although the importance of recur-
rent venous thrombosis is well recognized as a powerful
determinant of the postthrombotic syndrome,7,31,32 in-
volvement of the iliofemoral venous segment is associated
with at least as great amean change in Villalta score (2.23;
95% confidence interval [CI], 1.29-3.16) as a previous
ipsilateral DVT (1.78; 95% CI, 0.69-2.87).8 Finally, pa-
tients with extensive iliofemoral venous thrombosis have a
greater than twofold increased risk of recurrent VTE com-
pared with those with femoropopliteal thrombosis.6
Because involvement of the iliofemoral venous seg-
ments is associated with worse outcomes, the most prox-
imal extent of thrombus should be clearly defined in the
clinical management of patients as well as in research
studies and clinical trials. Routine use of the term prox-
imal venous thrombosis should be discouraged in favor
of more precise characterization of these thrombi as
involving the iliofemoral or femoropopliteal venous
segments.
1.2. If iliofemoral venous thrombosis is suspected
but not confirmed using standard diagnostic modalities
such as venous ultrasound imaging, we recommend the
use of adjunctive imaging modalities, such as computed
tomography venography or magnetic resonance venog-
raphy to characterize the most proximal thrombus ex-
tent (Grade 1C). Several strategies for the diagnosis of
DVT, incorporating combinations of clinical risk stratifica-
tion,33,34 measurement of D-dimer levels,35-39 and venous
ultrasound imaging, have been developed. As a component
of such strategies, venous ultrasound imaging has become
the most important diagnostic test for acute DVT. Com-
pared with venography, accuracy studies have shown du-
plex has a mean sensitivity and specificity of 97% and 94%,
with mean positive and negative predictive values of 97%
and 98% for symptomatic, proximal DVT.40 Unfortu-
nately, many ultrasound departments do not routinely eval-
uate the iliac veins, and even if examined, adequate imaging
of these segments is often limited by body habitus, depth,
overlying bowel gas, and incompressibility of the retroper-
itoneal veins. Although visualization of at least one iliac eein segment has been reported in up to 79% of ultrasound
tudies, the common iliac vein was adequately imaged in
nly 47%.41
Indirect findings in the common femoral vein, includ-
ng continuous venous flow, absent respiratory variation,
nd continuous flow with Valsalva, may suggest proximal
bstruction but cannot exclude nonocclusive thrombus or
xtrinsic compression. Contrast venography may similarly
ail to demonstrate the pelvic veins due to contrast dilution
y the unopacified deep pelvic veins.42
Because multiple venous segments are usually concur-
ently involved, a diagnosis of DVT can most often be
stablished independently of evaluating the iliac veins.
owever, for the reasons cited in recommendation 1.1,
stablishing the most proximal extent of thrombosis is
mportant in those patients, who may be candidates for
arly thrombus removal. Involvement of the iliac veins has
een reported in up to 23% of patients when complete
olor-flow ultrasound imaging, including the iliac veins, is
erformed.41 Isolated pelvic vein thrombosis has been re-
orted in 1% to 4% of studies using venography or ultra-
ound imaging, and evidence shows both of these modali-
ies underestimate the true incidence of isolated pelvic vein
hrombosis.43,44 Computed tomography venography
CTV) and magnetic resonance venography (MRV) are
etter able to evaluate the IVC and pelvic veins than
ltrasound imaging or contrast venography. Although
ikely biased by referral patterns, Spritzer44 found involve-
ent of the pelvic veins in 43.8% of 167 consecutive
ositive MRV studies. Thrombus was isolated to the pelvic
eins in 20.4% of these positive studies. Ultrasound imag-
ng failed to detect isolated iliac thrombosis in all seven
atients undergoing ultrasound imaging and MRV.
CTV may be performed by direct contrast administra-
ion into a foot vein or by indirect injection through an arm
ein.45 Indirect CTV may be performed as part of imaging
rotocols for pulmonary embolism (PE)46 and avoids the
eed for foot vein puncture in a swollen limb. Pooled
nalysis of 13 studies comparing CTV vs ultrasound imag-
ng or venography (largely in patients presenting with
ymptoms of PE) showed an overall sensitivity and speci-
city of 95.9% and 95.2% for the detection of DVT.47
maller studies have also shown that CTV has the capacity
o detect iliac thromboses that were missed on standard
ltrasound protocols.43
MRV has also been demonstrated to be accurate in the
iagnosis of DVT. A meta-analysis of 14 studies using a
ariety of MRV techniques compared with venography or
ltrasound imaging demonstrated a sensitivity and specific-
ty of 95.7% and 92.9%, respectively.48 In a series of 45
atients with acetabular fractures, Montgomery et al42
ound that contrast venography identified only one of 11
elvic thrombi documented byMRV. Others have similarly
hown MRV is accurate in the diagnosis of pelvic
hrombosis.49
If duplex ultrasound imaging suggests the presence of
liac thrombosis but is not able to define the most proximal
xtent of thrombus, it may be reasonable to proceed di-
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tion. However, further noninvasive imaging of the pelvis
with CTV or MRV should be considered when a clinical
suspicion of DVT persists despite a negative result on an
ultrasound examination. If iliofemoral thrombus is identi-
fied, definitive contrast imaging can be performed at the
time of any planned intervention.
Selection of the appropriate study depends on patient
characteristics and institutional expertise. In strongly rec-
ommending the use of alternative imaging in such situa-
tions, a high value is placed on identifying isolated iliofem-
oral thrombosis that may be missed by routine ultrasound
imaging, although the cost-effectiveness of this approach
has not been evaluated nor have prospective management
trials been performed (Grade 1C).
2. Indications for early thrombus removal
2.1. We suggest a strategy of early thrombus re-
moval in selected patients meeting the following crite-
ria: (a) a first episode of acute iliofemoral deep venous
thrombosis, (b) symptoms <14 days in duration, (c) a
low risk of bleeding, and (d) ambulatory with good
functional capacity and an acceptable life expectancy
(Grade 2C). The strength of recommendation for strate-
gies of early thrombus removal are based on balancing the
patient-important benefits of prevention of the postthrom-
botic syndrome and quality of life vs the risks of therapy;
specifically, bleeding, PE, and recurrent DVT. The use of
surrogate outcomes may also be relevant, such as the pre-
vention of venous reflux and persistent venous obstruction,
although they provide a less robust estimate of benefit and
contribute to the indirectness of the evidence. Overall, the
quality of evidence supporting early thrombus removal
strategies is very low (Grade C) because of the methodo-
logic limitations of the relevant studies (lack of randomiza-
tion, incomparability of study groups, loss to follow-up),
imprecise estimates of effects, and indirectness of the
evidence.19
However, the available evidence does suggest that early
thrombus removal strategies for iliofemoral venous thrombo-
sis are associated with significant reductions in manifestations
of the postthrombotic syndrome as well as improvements in
the surrogate markers of valvular incompetence (reflux) and
persistent venous obstruction.19 Competing risks in-
clude those associated with surgery (surgical thrombec-
tomy) and bleeding (thrombolytic strategies). System-
atic review of comparative studies suggests that adverse
events are poorly reported overall19 and that caution is
warranted in ensuring patients are appropriately selected.
The balance of risks vs benefits for individual early
thrombus removal strategies are further discussed below.
Less rigorous evidence suggests that the optimal pa-
tient population includes patients with a first episode of
iliofemoral DVT of14 days in duration, having a reason-
able life expectancy, and without a high risk of bleeding.
Recommendations regarding the optimal patient popula-
tion are largely derived from one large, multicenter registry
of patients undergoing catheter-directed pharmacologic vhrombolysis.16 Among patients enrolled in the National
enous Registry, those with chronic symptoms, femoro-
opliteal DVT, and symptoms 10 days in duration had
ignificantly worse outcomes than those with a first episode
f acute iliofemoral DVT of 10 days in duration. How-
ver, the 10-day interval of symptoms was arbitrary, and
ymptom duration among those symptomatic for10 days
aried from days to many months.
Other guidelines have suggested that DVT associated
ith symptoms present for 14 days be considered
cute,27 and a recently published randomized trial included
atients with symptoms of 21 days.50 These recommen-
ations contrast with the findings of our systematic re-
iew,19 which identified no relationship between the dura-
ion of symptoms before intervention and development of
he postthrombotic syndrome. On balance, recommenda-
ions for consideration of early thrombus removal strategies
n patients with symptoms of 14 days of duration would
eem fairly secure. Although a benefit in patients with a
uration of symptoms of 14 days cannot be excluded,
hronic thrombosis does appear to be associated with infe-
ior results,16 and the relative benefits vs risks in such
atients should be considered on an individualized basis.
Given the options available for the treatment of acute
liofemoral DVT, it is unlikely that all patients would
hoose a strategy of surgical thrombectomy, catheter-
irected pharmacologic thrombolysis, or pharmacomechani-
al thrombolysis. Individual patients undoubtedly place
ifferent values on the benefits of avoiding the post-
hrombotic syndrome vs the risks and burdens of a surgical
rocedure or bleeding. Most patients place a higher value
n avoiding early death than on avoiding late outcomes
hat affect quality of life.51
A decision analysis evaluating systemic streptokinase in
he treatment of DVT suggests that patients would be
nlikely to accept more than a 1.7-fold increase in major
leeding compared with heparin therapy.51 On the basis of
ndividual variation in values and preferences, strategies of
arly thrombus removal should be considered a Grade 2
ecommendation. Recommendation of a strategy of early
hrombus removal requires a careful assessment of the
otential risks and benefits for the individual patient, and
or those patients in whom early thrombus removal is
eemed a reasonable therapeutic option, a careful discus-
ion with the patient to ensure that the physician’s recom-
endation is concordant with the patient’s values and
references.
2.2. We recommend early thrombus removal strat-
gies as the treatment of choice in patients with limb-
hreatening venous ischemia due to iliofemoral deep
enous thrombosis with or without associated femoro-
opliteal venous thrombosis (phlegmasia cerulea do-
ens) (Grade 1A). Phlegmasia cerulea dolens (PCD) is
haracterized bymassive swelling, cyanosis, and pain result-
ng from extensive thrombosis of the iliofemoral venous
utflow.52,53 Pedal pulses remain palpable in 50% of
atients.54,55 Massive fluid sequestration may lead to hypo-
olemia and hypotension. Venous gangrene may compli-
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Volume 55, Number 5 Meissner et al 1455cate 60% to 64% of cases of PCD52,54 and occurs when
extensive venous thrombosis, most often at the iliofemoral
level, leads to profound venous hypertension and small
arterial collapse once critical closing pressures are exceeded
by the surrounding tissue pressure.56 Calf compartment
pressures of 50 mm Hg have been documented in asso-
ciation with PCD.53,57
Unfortunately, the literature regarding venous gangrene
is fragmented, with the surgical literature emphasizing the
mechanical consequences of venous outflow obstruction and
themedical literature largely focusing onmicrovascularmech-
anisms. Venous gangrene may be associated with profound
imbalances of the procoagulant–anticoagulant systems, partic-
ularly in the setting of underlying malignancy or heparin-
induced thrombocytopenia, both of which are common un-
derlying causes.54,58,59 Venous gangrene in these situations is
often associatedwith the initiation ofwarfarin and results from
a combinationof profoundhypercoagulability and concurrent
protein C depletion.60 However, it is unclear how much
overlap there is between reports of venous gangrene arising
from extensive venous outflow obstruction and those related
to an underlying procoagulant–anticoagulant imbalance. The
development of limb-threatening venous ischemia may thus
be multifactorial, related to elevated venous pressures as well
as profound procoagulant–anticoagulant imbalances. Regard-
less of the mechanism, venous gangrene is associated with
death in one-third or more of patients and high rates of
amputation.52,54,57,59
The primary goals in the treatment of PCD with im-
pending tissue loss are arresting thrombus progression,
thereby preserving patency of the collateral circulation, and
restoring venous outflow. Appropriate anticoagulation,
fluid resuscitation, and leg elevation are important early in
the management of PCD.53,57 The ACCP has developed
guidelines for the management of venous gangrene in the
setting of heparin-induced thrombocytopenia.61 These
guidelines strongly recommend anticoagulation with a
nonheparin anticoagulant (Grade 1B) until the platelet
count has stabilized at a normal level. Warfarin should not
be instituted until the platelet count has recovered (Grade
1B). The clinician should consult the ACCP guidelines for
full details of the anticoagulant management of venous
gangrene associated with heparin-induced thrombocytope-
nia.61 Although heparin is effective in cancer-associated
thrombosis, institution of warfarin may also lead to venous
gangrene and should be approached with caution.58
Despite the critical importance of appropriate anticoagu-
lation in arresting thrombus progression, such treatment does
little to address underlying mechanical issues related to pro-
found venous outflow obstruction. Older reviews of the liter-
ature suggested that heparin alone was ineffective in the treat-
ment of venous gangrene.52 We recommend that all patients
with impending tissue loss related to venous thrombosis be
evaluated for iliofemoral venous outflow obstruction as
well as potential causes of profound hypercoagulability
such as malignancy and heparin-induced thrombocytope-
nia. Anticoagulation should be initiated according to the eCCP guidelines,24 with careful attention to the possibility
f heparin-induced thrombocytopenia or malignancy.61
Although the evidence is of low quality and largely
imited to case reports and series, thrombolytic therapy
oes appear to limit the progression of pregangrenous
hanges in patients with profound iliofemoral venous out-
ow obstruction. Several reports document the efficacy of
harmacomechanical or catheter-directed pharmacologic
hrombolysis in limiting or reversing ischemic changes due
o PCD.57,62,63 Despite concerns regarding the quality of
he data, the potential benefits appear to outweigh the risks
n this life- and limb-threatening condition. The relative
nfrequency of PCD with impending tissue loss, the heter-
geneity of patients, and the poor results of anticoagulation
lone make it unlikely that large randomized trials will be
erformed. Furthermore, the results of conventional anti-
oagulation are sufficiently dismal that catheter-directed
harmacologic thrombolysis for impending venous gan-
rene in the presence of iliofemoral thrombosis is strongly
ecommended (Grade 1A).
Although older series recommended fasciotomy for
ompartment syndrome associated with PCD,15,64 its role
n contemporary management is controversial. However,
e must emphasize that fasciotomy is not first-line therapy,
hould not precede rapid intervention to relieve iliofemoral
enous outflow obstruction, and should rarely be consid-
red as an isolated procedure. A decrease in compartmental
ressures will accompany successful relief of outflow ob-
truction53 and usually obviates the need for fasciotomy.
e suggest that fasciotomy only be considered if compart-
ent pressures in the thigh or calf remain elevated (30
m Hg) despite efforts to restore iliofemoral venous out-
ow using the procedures outlined above (Grade 2C).
asciotomy in the setting of thrombolytic therapy and
nticoagulation may be associated with significant blood
oss.
2.3. We recommend that patients with isolated
emoropopliteal deep venous thrombosis be managed
ith conventional anticoagulation therapy because
here is currently insufficient evidence to support early
hrombus removal strategies in this patient population
Grade 1C). The role of early thrombus removal in the
reatment of femoropopliteal DVT remains poorly defined.
onsensus-based documents have suggested that the
hreshold for thrombus removal strategies in acute femo-
opopliteal DVT should be higher than for iliofemoral
VT.27 Compared with iliofemoral DVT, femoropopliteal
VT is associated with less deranged hemodynamics, a
ower risk of the postthrombotic syndrome,8 and a lower
isk of recurrent VTE.6 Harvesting of the femoral vein as a
onduit for arterial reconstruction has been shown to be
olerated with few symptoms. Among 81 limbs in which
he femoropopliteal vein was harvested, mild edema was
eported in 31%, with no skin changes or ulceration.65 Late
ollow-up (70.1  5.6 months) of 28 such limbs showed
dvanced chronic venous disease (CEAP C3 to C6) in only
4.8%.66 Although such limbs may show plethysmographic
vidence of venous outflow obstruction,66 this is usually
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funda femoris vein through remnants of the axial limb
vein.67
Multicenter registries have further suggested a less
favorable outcome for femoropopliteal than for iliofemoral
DVT treated with thrombolytic therapy.16 Although an
effect of thrombus chronicity cannot be excluded, 1-year
patency was achieved in only 47% of limbs with femoropop-
liteal thrombosis compared with 64% of limbs with iliofem-
oral thrombosis. Complete lysis was not achieved in any
patient with femoropopliteal DVT present for 10 days.
Although recommendations may change with the availabil-
ity of better-quality evidence, there is currently little evi-
dence supporting a role for early thrombus removal strate-
gies in the treatment of femoropopliteal DVT. However,
we must acknowledge that the beneficial effects of early
thrombus removal were not substantially changed if studies
not explicitly evaluating the treatment of iliofemoral DVT
were included in the systematic review.19 This at least raises
the possibility that these strategies may have some role in
the treatment of femoropopliteal DVT.
3. Techniques for early thrombus removal
3.1. We suggest percutaneous catheter-based tech-
niques (pharmacologic or pharmacomechanical) as
first-line therapy for early thrombus removal in pa-
tients meeting the criteria in 1.1 (Grade 2C). Compa-
red with standard anticoagulant therapy, catheter-di-
rected pharmacologic thrombolytic therapy is associated
with significant reductions in the risks of the postthrom-
botic syndrome (relative risk [RR], 0.19; 95% CI .07-
.48), venous reflux (RR, 0.21; 95% CI, 0.09-0.53), and
venous obstruction (RR, 0.35; 95% CI, 0.17-0.34).19
These results are consistent with a previous systematic
review,20 which included less efficient systemic and lo-
coregional techniques, demonstrating a significant re-
duction in postthrombotic syndrome (RR, 0.66; 95% CI,
0.47-0.94) with thrombolytic treatment. According to
this review, one case of postthrombotic syndrome would
be prevented for every five patients treated with throm-
bolytic therapy. The short-term hemodynamic results of
one additional randomized clinical trial in which cathe-
ter-directed pharmacologic thrombolysis was compared
with standard anticoagulation has been published since
the most recent systematic review.50 Among 103 ran-
domized patients, 6-month patency was significantly better
in those who received catheter-directed pharmacologic
thrombolysis (64.0% vs 35.8%; P  .004), whereas the
incidence of femoral vein reflux was similar (60.0% vs
66.0%; P  .53).
Contraindications to thrombolytic therapy include ac-
tive internal bleeding; recent cerebrovascular accident or
intracranial surgery, trauma, or tumor; recent serious gas-
trointestinal bleeding; major trauma or surgery 10 days;
severe uncontrolled hypertension; pregnancy; endocarditis;
intracardiac thrombus; known right-to-left shunt; coagu-
lopathy, thrombocytopenia, or absolute contraindications
to anticoagulation; suspected septic thrombus; and allergy to thrombolytic agents.16,27 Although most contraindica-
ions can be identified on routine clinical assessment,
ome68 have suggested brain imaging before thrombolysis
n patients with malignancies known to metastasize to the
entral nervous system.
The associated risks of catheter-directed thrombolysis
nclude hemorrhage (particularly intracranial), PE, and re-
urrent DVT. Although complications have been poorly
eported in comparative trials, some data regarding the
leeding complications associated with catheter-directed
hrombolytic therapy are available. Among 473 patients
eported in the multicenter National Venous Registry,
leeding complications were reported in 54 (11%), neuro-
ogic complications in two (0.4%), PE in six (1%), and death
n two (0.4%). Bleeding complications were most common
t the venous insertion site (4%) or in the retroperitoneum
1%). Major neurologic complications, including one fatal
ntracranial hemorrhage and one subdural hematoma, oc-
urred in only two patients (0.4%).
A systematic review that included trials of systemic and
ocoregional thrombolysis reported higher rates of bleed-
ng among patients treated with thrombolytic agents (RR,
.73; 95% CI 1.04-2.88) but no significant differences in
ortality (RR, 0.84; 95% CI, 0.29-2.42), pulmonary em-
olism (RR, 1.23; 95% CI, 0.34-4.45), or intracranial
emorrhage (RR, 1.70; 95% CI, 0.21-13.70).20 Notably,
hese authors observed that bleeding complications, which
ccurred in 10% of thrombolytic patients compared with
% of patients treated with anticoagulation, tended to
ecrease over time, perhaps reflecting improved thrombo-
ytic techniques and more rigorous exclusion criteria. Fi-
ally, a pooled analysis of 19 studies, largely single-center
ase series, reported major bleeding in a mean of 8.3% of
atients (range, 0%-24%) and rates of symptomatic PE,
ntracranial hemorrhage, and death of 0.9% (range, 0%-
%), 0.2% (range, 0%-1%), and 0.3% (range, 0%-1%),
espectively.27
There are little comparative data evaluating optimal
hrombolytic agents, doses of lytic agents and concurrent
nticoagulants, and infusion techniques. Streptokinase, al-
hough rarely used due to the risks of allergic reactions and
leeding, remains the only thrombolytic agent approved by
he United States Food and Drug Administration for the
reatment of DVT. Several series, however, have reported
he successful use of urokinase,16,69-72 tissue plasminogen
ctivator,69-71 reteplase,69-71 and tenecteplase73 for venous
hrombolysis.
A consensus panel of the Society of Interventional
adiology has reviewed recommended thrombolytic dos-
ges and techniques for their catheter-directed administra-
ion.68 Because patient characteristics and bleeding risks
ary, individual judgment is required in the selection of
ppropriate thrombolytic and concurrent anticoagulant
oses. Most would agree that thrombolytic infusion times
hould be minimized and balanced against lytic progress to
void complications. Reimaging with follow-up venogra-
hy at 8- to 24-hour intervals68 and discontinuation of
herapy once lytic stagnation is reached are commonly
t
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tionated heparin is recommended during thrombolytic
procedures, although doses may differ depending on the
thrombolytic agent and there is no robust scientific evi-
dence to guide dosing. Previous consensus recommenda-
tions from the Society of Interventional Radiology suggest
that subtherapeutic doses of heparin are appropriate for all
thrombolytic agents except urokinase, in which case thera-
peutic anticoagulation may be considered.68
3.2. We suggest a strategy of pharmacomechanical
thrombolysis be considered over catheter-directed
pharmacologic thrombolysis alone if expertise and re-
sources are available (Grade 2C). Although more effi-
cient than the systemic administration of thrombolytic
agents, catheter-directed pharmacologic thrombolysis re-
mains limited by prolonged infusion times (averaging 53.4
hours), the potential for bleeding complications,20 and the
frequent requirement for hospitalization in the intensive
care unit.71 A variety of mechanical devices have been
designed to work in conjunction with thrombolytic agents
in an effort to improve the efficiency of thrombolysis,
reduce lytic doses and procedure times, and lessen bleeding
complications. These approaches, which include rotational,
rheolytic, and ultrasound-assisted devices, are collectively
referred to as pharmacomechanical thrombolysis.17,74 Lim-
ited data suggest that these devices should be used in
conjunction with pharmacologic lytic agents, significant
lysis (50%) being achieved in only one-third of patients
treated with mechanical devices alone.70 The use of me-
chanical devices alone, without the concurrent use of
thrombolytic drugs, cannot be routinely recommended.
A systematic review of 16 retrospective case series that
used a pharmacomechanical approach with a variety of
thrombolytic devices reported 50% lysis in 83% to 100%
of patients. Although complication rates should be viewed
with caution, these studies reported no procedure-related
deaths or strokes, a 1% incidence of PE, and no major
bleeding complications, although 4.2% to 14% of patients
required a transfusion.17 A similar systematic review of
eight cases series also found nomajor periprocedural bleed-
ing complications or deaths.74
Although randomized clinical trials are lacking, two
small cohort studies compared pharmacomechanical
thrombolysis with catheter-directed pharmacologic throm-
bolysis. Lin et al reported that although rates of complete
thrombolysis were similar for pharmacomechanical and
catheter-directed pharmacologic thrombolysis (75% vs
70%), infusion times (76  34 minutes vs 18  8 hours)
and costs (mean cost difference $37, 609) were signifi-
cantly less with pharmacomechanical thrombolysis. There
was no difference in bleeding complications, although pa-
tients undergoing pharmacomechanical thrombolysis re-
quired fewer transfusions (0.2 vs 1.2 units). The second
small study (n  45) similarly demonstrated shorter treat-
ment times (30.3  17.8 vs 56.5  27.4 hours) and lower
urokinase doses (2.95  1.8 million U vs 6.70  5.90
million U) for adjunctive pharmacomechanical thrombol-
ysis compared with catheter-directed pharmacologic 2hrombolysis alone. Major bleeding complications were
.1% for adjunctive pharmacomechanical thrombolysis vs
.7% for catheter-directed pharmacologic thrombolysis
lone, which was not significantly different.72
Because no direct comparisons regarding the efficacy of
atheter-directed pharmacologic vs pharmacomechanical
hrombolysis were available at the time of the current
ystematic review, the efficacy of these devices in preventing
he postthrombotic syndrome is indirectly inferred from
he data regarding pharmacologic catheter-directed lysis
lone. However, their preferential recommendation over
harmacologic catheter-directed lysis is based on the po-
ential for greater efficacy and safety.
3.3. We suggest open surgical venous thrombec-
omy in selected patients who are candidates for anti-
oagulation but in whom thrombolytic therapy is con-
raindicated (Grade 2C). Venous thrombectomy is
ffective in relieving iliofemoral venous obstruction and
ay preserve function of more distal valves. Iliofemoral
enous thrombectomy has been compared with anticoagu-
ation therapy in 10 studies,52,75-83 only one of which was a
rospective, randomized trial.80 All studies were small,
anging from 15 to 192 patients, with follow-up varying
rom 6 months to 10 years. However, pooled analysis19 of
he five studies75-77,80,83 evaluating reflux showed throm-
ectomy was associated with a statistically significant reduc-
ion in the risk of reflux (RR, 0.68; 95% CI, 0.46-0.99).
mong the four studies75,80,82,83 evaluating venous pa-
ency, there was a nonsignificant trend toward less venous
bstruction (RR, 0.84; 95% CI, 0.60-1.19) among those
ndergoing thrombectomy. Most important, there was a
ignificant reduction in the risk of the patient-important
utcome of the postthrombotic syndrome (RR, 0.67; 95%
I, 0.52-0.87). Unfortunately, pooled analysis19 of these
ine trials yielded no reliable data regarding the risk of
omplications or death. As with all strategies of early
hrombus removal, careful attention to patient selection
nd an individual assessment of risks vs benefits as well as
atient values and preferences is required in recommending
liofemoral venous thrombectomy.
The specific thrombectomy techniques and adjuvants
sed for catheter-directed and pharmacomechanical throm-
olysis techniques are largely guided by case series and expert
pinion rather than by comparative trials. Important technical
spects of the procedure include preoperative imaging to
emonstrate the proximal extent of thrombus with an ex-
ended surgical approach if the IVC is involved; intraoperative
se of positive end-expiratory pressure to reduce the risk of PE;
ntraoperative completion venography to ensure patency of the
liac vein; stenting of any identified iliac vein lesions; use of a
emporaryarteriovenousfistula to reduceearly rethrombosis; and
arefully monitored postoperative anticoagulation.15,84
Although thrombectomy does appear to be associ-
ted with improved long-term outcomes after iliofemo-
al DVT, the overall quality of the data supporting its use
s low, and there are little data allowing a reliable esti-
ate of risk vs benefits in an individual patient19 (Grade
C). The interval estimates are wide, but there is a trend
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bolysis than with thrombectomy with respect to the risk
of the postthrombotic syndrome (RR, 0.33; 95% CI,
0.00-2.28), venous reflux (RR, 0.44; 95% CI, 0.05-
2.10), and venous obstruction (RR, 0.30; 95% CI, 0.01-
2.13).8 We acknowledge that these data suffer from
indirect comparison, wide CIs, and potential confound-
ing by the discordant time intervals during which the
studies were performed.
In recommending the thrombolytic techniques over
surgical thrombectomy in patients who are candidates for
either approach, a higher value is placed on avoiding the
more invasive procedure and potential surgical complica-
tions than on unknown differences in bleeding rates. How-
ever, given the more invasive nature, the limited experience
of most surgeons, and the potentially greater risk of com-
plications with surgical thrombectomy, the weight of the
evidence would seem to favor percutaneous thrombolytic
approaches over surgical thrombectomy in patients without
contraindications to thrombolytic agents.
4. Periprocedural inferior vena cava filters
4.1. We recommend against routine use of inferior
vena cava filters (permanent or temporary) in conjunc-
tion with catheter-directed pharmacologic thromboly-
sis of the iliofemoral venous segments (Grade 1C). Al-
though catheter-directed pharmacologic thrombolysis may
be associated with asymptomatic radiographic evidence of
PE,85 symptomatic PE appears to be a relatively rare com-
plication of catheter-directed pharmacologic thrombolysis.
Among the 473 patients included in the National Venous
Registry,16 in whom IVC filters were not routinely used,
PE occurred in only 1% of patients. Notably, 71% of proce-
dures involved thrombus extension to at least the iliofemoral
segments, and 15% had extension to the IVC. The mean
incidence of PE was 0.9% in a pooled analysis of 19 published
studies of catheter-directed or pharmacomechanical throm-
bolysis.27 This risk is similar to that observed in patients
treated with conventional anticoagulation and does not war-
rant routine placement of an IVC filter.
4.2. We suggest that the relative risks vs benefits of
periprocedural retrievable inferior vena cava placement
be considered in patients undergoing pharmacom-
echanical thrombolysis and in those with thrombus
extending into the inferior vena cava or who have
markedly limited cardiopulmonary reserve (Grade 2
C). Although the routine use of IVC filters in patients
undergoing catheter-directed pharmacologic thrombol-
ysis appears to be unwarranted, the selective use of such
devices in high-risk situations remains controversial. Pa-
tients with thrombus extending into the IVC and those
undergoing pharmacomechanical thrombolysis71,73 are
often deemed to be at higher risk for PE and to warrant
consideration for retrievable filter placement.69,86 Un-
fortunately, little reliable data are available to support or
refute this position.
Among 68 patients undergoing a variety of pharma-
cologic (40%), mechanical (17%), and pharmacom- schanical procedures, there were no symptomatic
eriprocedural PE among those with (20%) or without
VC filters.69 Although there may have been a selection
ias among those undergoing prophylactic filter place-
ent, these results were achieved despite thrombus ex-
ending into the IVC in 30% of patients. Other small
eries85 have similarly reported asymptomatic emboli
aptured by IVC filters in similar proportions of patients
ndergoing catheter-directed or pharmacomechanical
hrombolysis and among those with and without in-
olvement of the IVC. However, it is also clear that
ymptomatic PE may occasionally complicate these pro-
edures.87 Given that there are little reliable data regard-
ng the risk of PE with the newer pharmacomechanical
odalities and that filter placement is generally associ-
ted with little morbidity (but additional cost), it seems
rudent to consider this an unresolved question and to at
east consider the relative balance of benefit vs risk in
otentially high-risk situations (Grade 2C).
. Adjunctive use of venous stents
5.1. We recommend the use of self-expanding me-
allic stents for treatment of chronic iliocaval compres-
ive or obstructive lesions that are uncovered by any of
he thrombus removal strategies (Grade 1C). and
5.2. We suggest that stents not be used in the
emoral and popliteal veins (Grade 2C). Acute DVT is
sually regarded as a multicausal disease, arising from the
nteraction of multiple genetic, environmental, and behav-
or risk factors.88,89 The importance of underlying ana-
omic factors, such as nonthrombotic iliac vein lesions,90
as not appreciated when conventional anticoagulation
as the only therapeutic option. However, with the devel-
pment of image-guided techniques for early thrombus
emoval, including surgical thrombectomy and thrombo-
ytic strategies, it has become clear that compressive or
bstructive iliac vein lesions contribute to many cases of
liofemoral DVT. A pooled analysis of 19 published studies,
ncluding 1046 patients treated with catheter-directed or
harmacomechanical thrombolysis, reported the use of
tents in 46% of patients.27 Although the total number of
imbs with stenoses or obstructive lesions uncovered by
ytic therapy in the National Venous Registry was not
eported, 33% of limbs required treatment with metallic
tents.16 The 1-year patency was significantly better in
imbs treated with iliac stents (74%) than in limbs without
tent placement (53%; P  .001).
Although lacking evidence from comparative trials, the
elatively poor results associated with untreated iliac steno-
is and the poor results achieved with angioplasty favor
tenting of any persistent obstructive lesions uncovered by
hrombolysis and is strongly recommended (Grade 1C).
ingle-plane venography may be relatively insensitive in the
etection of iliocaval compression. Compared with intra-
ascular ultrasound, venography has been demonstrated to
ave a sensitivity of only 45% for the detection of chronic
liac obstruction.91 Although likely a useful adjunct in this
etting, there are currently little data regarding the use of
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Volume 55, Number 5 Meissner et al 1459intravascular ultrasound imaging to assess residual stenosis
and guide stent placement after early thrombus removal.
Flexible, large-diameter, self-expanding stents, extending
into the inferior vena cava and common femoral vein if
indicated, are preferred for use in the iliac veins. In contrast
to the favorable results with iliac stents, stents placed in the
femoropopliteal venous segment fare poorly,16 and we
suggest that stents not be used in the femoropopliteal
segment (Grade 2C).
6. Early thrombus removal strategies as an adjuvant
to conventional management
6.1. We recommend that patients managed with
early thrombus removal be treated with a standard
course of conventional anticoagulation after the proce-
dure (Grade 1A). Strategies of early thrombus removal
should be considered an adjunct rather than an alternative
to conventional anticoagulation for acute iliofemoral DVT.
Successful thrombus removal should be followed by a
standard course of anticoagulation with unfractionated or
low-molecular-weight heparin, followed by oral anticoag-
ulants administered for a duration guided by the patient’s
underlying risk factors. Evidence-based guidelines for the
anticoagulant treatment of acute DVT are regularly up-
dated by the ACCP.24 With anticoagulation, cumulative
rates of freedom from recurrent DVT after thrombolytic
treatment have been reported to be 85%, 83%, and 83% at
6, 12, and 24 months.69 Although the duration of antico-
agulation is generally determined by underlying throm-
botic risk factors, the optimal duration of anticoagulation
after the placement of venous stents in the setting of early
thrombus removal has not been adequately studied, and no
evidence-based recommendations can be provided. Factors
associated with stent thrombosis have included thrombo-
philia and evidence of extrinsic compression.92
6.2. We recommend that all patients be treated
with knee-high compression stockings (30 to 40 mm
Hg) for at least 2 years after the procedure (Grade
1C). The role of compression stockings in the manage-
ment of chronic venous disorders has been well estab-
lished.93 Compression stockings improve calf muscle pump
function, reduce edema, and likely improve cutaneous mi-
crocirculation.94-98 The use of graded elastic compression
stockings decreases by 50% the incidence of objectively
defined postthrombotic syndrome after a first episode of
“proximal” DVT treated with conventional anticoagulation.
In a randomized trial of 194 patients, the incidence of mild-
to-moderate and severe postthrombotic syndrome was 20%
and 11%, respectively, among patients receiving compression
stockings compared with 47% and 23% among those in the
control group.99 Prandoni et al100 similarly found the use of
compression stockings (30 to 40 mm Hg at the ankle) re-
duced the 2-year incidence of any post-thrombotic syndrome
from 49.1% to 24.5%. Among those treated with optimal
anticoagulation, 4.3 patients need towear compression stock-
ings to prevent one case of post-thrombotic syndrome.
On the basis of these data, current guidelines recom-
mend the prescription of graded elastic compression stock- tngs (40 mm Hg at the ankle) for at least 2 years after a
roximal thrombotic event treated with conventional anti-
oagulation (Grade 1A).24 Although early thrombus re-
oval strategies likely also reduce the incidence of the
ostthrombotic syndrome, no reports have evaluated the
djunctive effect of compression stockings in this patient
opulation. The evidence supporting the use of compres-
ion stockings among patients treated with early thrombus
emoval strategies is indirect, but the potential benefits
ikely exceed the risks, and their use can be strongly recom-
ended (Grade 1C).
ALUES STATEMENT
The committee incorporated certain factors other than
vidence in formulating the recommendations presented in
hese guidelines. The explicit identification of such factors
s important for guideline users and represents an advantage
f using the GRADE system. The committee recognizes
he poor quality of evidence supporting several of the
ecommendations, particularly arising from the common
se of surrogate end points (eg, degree of lysis, venous
eflux and patency) and the sparse data demonstrating the
elative efficacy of different treatment strategies on patient-
mportant outcomes (eg, death, pulmonary embolism, re-
urrence of DVT, quality of life, and time to return to
ork). The committee placed a relatively high value on
reventing DVT and the postthrombotic syndrome. We
lso considered the availability of surgical/interventional
xpertise and the resources needed for more aggressive
pproaches. In recommending the thrombolytic tech-
iques over surgical thrombectomy, we placed a higher
alue on avoiding the potential complications of an infre-
uently performed surgical procedure. In recommending
tents for lesions uncovered by thrombus removal, we
ighly valued the avoidance of complications related to
ntreated iliac stenosis, despite the lack of comparative
ata. In recommending compression stockings, we consid-
red this intervention to be relatively inexpensive, to not
equire expertise, and able to be applied on a large scale.
ndirect evidence was occasionally used due to lack of more
irect evidence.
Evidence-based medicine has been defined as “the con-
cientious, explicit, and judicious use of the current best
vidence in making decisions about the care of individual
atients.”101 This specifically involves integrating clinical ex-
ertise, the patient’s individual situation and preferences, and
he best available clinical evidence. The guidelines of the
ociety for Vascular Surgery and American Venous Forum
hould be interpreted as a guide to be applied in the context of
linical judgment rather than as a rigidmandate. Furthermore,
here are many aspects of early thrombus removal strategies
or which little rigorous data exist and evidence-based guide-
ines are impractical at the present time.Clinical judgment is of
he utmost importance in such situations.
ONCLUSIONS
Unfortunately, the clinical evidence supporting vir-
ually all strategies of early thrombus removal, including
RJOURNAL OF VASCULAR SURGERY
May 20121460 Meissner et alcatheter-directed pharmacologic thrombolysis, pharma-
comechanical thrombolysis, and surgical thrombectomy,
is of low quality. Large multicenter randomized clinical
trials are lacking, and existing series have often included
diverse patients and have largely evaluated only technical
outcome measures.16,17,74 Despite these obvious defi-
ciencies, systematic review of studies comparing these
strategies with conventional anticoagulation does sug-
gest some benefit with respect to reducing the incidence
of the postthrombotic syndrome.19 Successful applica-
tion of any of these strategies requires careful patient
selection as well as a consideration of the patient’s un-
derlying values and preferences. Accordingly, most rec-
ommendations are weak (Grade 2). Furthermore, be-
cause of the very low quality of the underlying evidence,
the details of these recommendations are likely to change
as better-quality evidence becomes available. In this
regard, the use of patient-important outcomes, such as
quality of life or objective measures of the post-throm-
botic syndrome (Villalta score,102 Venous Clinical Sever-
ity Score103) should be strongly encouraged over tech-
nical outcomes such as lytic success and surrogate
markers such as reflux and residual venous obstruction.
Randomized clinical trials, including the ATTRACT104
(Acute Venous Thrombosis: Thrombus Removal with
Adjunctive Catheter-Directed Thrombolysis) and
CaVenT50,105 (Catheter-directed Venous Thrombolysis
in Acute Iliofemoral Vein Thrombosis) trials, are cur-
rently underway and will likely provide further evidence
regarding the clinical utility of these strategies. We an-
ticipate that the results of these trials will lead to guide-
line revisions.
The currently available evidence cannot address several
important questions. These include the optimal thrombo-
lytic dose, the relative safety and efficacy of different throm-
bolytic agents and mechanical thrombectomy devices, and
the appropriate intensity of anticoagulation to be used
during thrombolytic procedures. Also, too little data are
available to guide recommendations regarding the use of
adjuvants such as intermittent pneumatic compres-
sion.106,107 Finally, the quality-of-life benefits and cost-
effectiveness of this therapy need to be more thoroughly
evaluated.
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